Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Emerging Company Profile

Anticancer Bioscience: applying synthetic lethality to MYC-driven cancers

Emerging Company Profile: Chengdu-based ACB joins a growing wave of next-gen synthetic lethality companies 

June 14, 2021 2:44 PM UTC

With an initial focus on MYC-driven cancers, Anticancer Bioscience joins a growing wave of next-generation synthetic lethality companies looking beyond the DNA damage response pathway kinases that have dominated the space.

President and CEO Dun Yang launched Anticancer Bioscience Ltd. (ACB) in 2016 to develop and commercialize research out of the J. Michael Bishop Institute of Cancer Research in Chengdu, which he directs. Yang completed his postdoc at the University of California San Francisco under Bishop, a Nobel Laureate whose group discovered and was first to clone MYC...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Anticancer Bioscience Ltd.